Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes

克里唑蒂尼 医学 肺癌 内科学 间变性淋巴瘤激酶 肿瘤科 融合基因 血液学 胃肠病学 碱性抑制剂 基因 生物 遗传学 恶性胸腔积液
作者
Panwen Tian,Yujie Liu,Hao Zeng,Yuan Tang,Analyn Lizaso,Junyi Ye,Lin Shao,Yalun Li
出处
期刊:Journal of Cancer Research and Clinical Oncology [Springer Science+Business Media]
卷期号:146 (4): 935-944 被引量:29
标识
DOI:10.1007/s00432-019-03116-6
摘要

This study aimed to determine the molecular features and clinical outcomes of young patients with non-small cell lung cancer (NSCLC) harboring ALK fusion genes. We interrogated the genomic profile of 1652 patients with lung cancer who underwent targeted next-generation sequencing to screen for candidate oncogenic drivers using histological specimens acquired from January 2016 to December 2018. ALK fusions were identified in 101 NSCLC patients, and 52 of them were diagnosed before the age of 50 years (52/367, 14.2%). Of the 52 patients with early-onset disease, 22 (42.3%) were male and 43 (82.7%) never smoked; the median patient age was 44 years (range 28–50 years). The most frequently occurring ALK fusion partner was EML4, which was identified in 80.8% (42/52) of young patients. Compared to the older patients, patients with early-onset disease were more likely to harbor EML4-ALK variant 1 (38.5% vs. 14.3%; P = 0.007). We also identified rare ALK fusions, including CHRNA7-ALK, TACR1-ALK, HIP1-ALK, DYSF-ALK and ITGAV-ALK, in patients with early-onset disease, and patients with these fusions responded well to crizotinib treatment. A statistically significant difference was observed in progression-free survival (PFS) between the young patients and older patients who received crizotinib as the first-line therapy (17.5 months vs 9.0 months, P = 0.048). However, the median PFS of young patients harboring concurrent TP53 mutations was only 6.2 months. Unique genetic characteristics were found in ALK-rearranged NSCLC patients with early disease onset, and these patients responded better to crizotinib and had longer PFS compared to patients with later disease onset. However, patients with concomitant TP53 mutations may not have a significant response to treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
刚刚
Minicoper发布了新的文献求助10
刚刚
背书强完成签到 ,获得积分10
1秒前
淡然以柳完成签到 ,获得积分10
3秒前
dolabmu完成签到 ,获得积分10
6秒前
崔崔完成签到 ,获得积分10
10秒前
SYLH应助xcxc采纳,获得10
11秒前
wp4455777完成签到,获得积分10
12秒前
十一完成签到,获得积分10
12秒前
ru完成签到 ,获得积分10
14秒前
慧木完成签到 ,获得积分10
14秒前
WW完成签到 ,获得积分10
15秒前
小高同学完成签到,获得积分10
16秒前
轻轻1完成签到,获得积分10
19秒前
20秒前
大橙子发布了新的文献求助10
24秒前
iuhgnor完成签到,获得积分10
27秒前
可夫司机完成签到 ,获得积分10
30秒前
yang完成签到,获得积分10
32秒前
一1完成签到 ,获得积分10
34秒前
jiaolulu完成签到,获得积分10
34秒前
量子星尘发布了新的文献求助10
36秒前
爆米花应助LiZhao采纳,获得10
36秒前
轻轻完成签到,获得积分10
39秒前
Orange应助jiaolulu采纳,获得10
39秒前
xcxc完成签到,获得积分10
41秒前
water应助科研通管家采纳,获得50
41秒前
41秒前
默存完成签到,获得积分10
44秒前
风中的金鱼完成签到 ,获得积分10
46秒前
橙汁完成签到,获得积分10
47秒前
普鲁卡因发布了新的文献求助10
50秒前
cora完成签到 ,获得积分10
56秒前
徐伟康完成签到 ,获得积分10
56秒前
Minicoper完成签到,获得积分10
1分钟前
科研通AI5应助普鲁卡因采纳,获得10
1分钟前
111完成签到 ,获得积分10
1分钟前
奥特曼完成签到 ,获得积分10
1分钟前
苏苏完成签到,获得积分10
1分钟前
大橙子完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022